Læknaneminn - 01.04.2004, Blaðsíða 31

MJ, ritstj. Primer on the Metabolic Bone Diseases and Disorders of Míneral
Metabolism. Lippincott Williams & Wilkins, 4. útg. 1999:208-212.
13. Holick MF. Vitamin D: Photobiology, metabolism mechanism of action and
clinical applications. í Favus MJ, ritstj. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism, Lippincott Williams & Wilkins, 4, útg. 1999:92-
98.
14. Bushinsky DA, Monk RD. Electrolyte quintet: Calcium. Lancet 1998; 352:305-
311.
15. CancerNetTM. Hypercacemia (PDQ®) Supportive Care Health Professionals
(á veraldarvefnum sem: http:/cancer.gov/canceringfo/pdq/supportivecare/
hypercalcemia/health-professional/).
16. Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone
disease. Annu Rev Med 1999;50:237-248.
17. Body JJ, Mancini I. Bisphosphonates for cancer patients: Why, how, and when?
Support Care Cancer 2000;10:399-407.
18. Fleisch, H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-
100.
19. Nussbaum SR, Younger J, Vandepol CJ. Single-dose intravenous therapy with
pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-,
60-, and 90-mg dosages. Am J Med 1993;95:297-304.
20. Wimalawansa SJ. Optimal frequency of administration of pamidronate in
patients with hypercalcemia of malignancy. Clin Endocrinol 1994;41:591 -595.
21. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for
the treatment of hypercalcemia of malignancy. The Oncologist 2002;7:481-491.
22. Ljunghall S. Use of clodronate and calcitonin in hypercalcemia due to
malignancy, Recent Results Cancer Res 1989;116:40-45.
23. Warrell RP, Murphy WK, Schulman P, et al. A randomized double-blind study
of gallium nitrate compared with etidronate for acute control of cancer-related
hypercalcemia. J Clin Oncol 1991; 9:1467-1475.
24. Perlia CP, Gubisch NJ, Wolter J, et al. Mithramycin treatment of hypercalcemia.
Cancer 1970;25: 389-394.
25. Montillo M, Miqueleiz S, Ricci F, Tedeschi A, Morra E. Tumor lysis syndrome in
hematologic malignancies: Prediction and management. Haematologica 2003;88
(suppl. 6):2-8.
26. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg
H. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia
in patients with cancer: report of an international compassionate use study. Cancer
2003;98:1048-1054.
27. Bach F, Larsen BH; Rohde K, Borgesen SE, Gjerris F, Boge-Rasmussen
T, Agerlin N, Rasmusson B, Stjernholm P, Sorensen PS, Metastatic spinal cord
compression. Occurrence, symptoms, clinical presentations and prognosis in 398
patients with spinal cord compression. Acta Neurochir 1990;107:37-43.
28. Byrne TN. Spinal cord compression from epidural metastases. N Engl J Med
1992; 327:614-619.
29. Bilsky MH, Lis E, Raizer J, Lee H, Boland P. The diagnosis and treatment of
metastatic spinal tumor. The Oncologist 1999;4:459-469.
30. DeAngelis LM, Posner JP. Neurologic complications. í Bast RC, Kufe DW,
Pollock RE, Weichselbaum RR, Holland JF, Frei E. Cancer medicine. American
Cancer Society og B.C. Decker 5. útg. 2000:2251-2270.
31. Quinn JA, DeAngelis LM. Neurologic emergencies in the cancer patient. Semin
Oncol 2000;27:311-321.
32. Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal
cord compression: an evidence-based guideline. J Clin Oncol 1998; 16:1613-
1624.
33. Mack EE. Neurolomuscular complications. I Casciato DA, Lowitz BB, ritstj.
Manual of Clinical Oncology. Lippincott Williams & Wilkins, 4. útg.2000. 586-600.
34. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose
dexamethasone in carcinomatous metastatic spinal cord compression treated with
radiotherapy: a randomised trial. Eur J Cancer 1994;30:22-27.
35. Heimdal K, Hirschberg H, Slettebo H, Watne K, Nome O. High incidence
of serious side effects of high-dose dexamethasone treatment in patients with
epidural spinal cord compression. J Neurooncol 1992;12:141-144.
36. Janjan NA. Radiotherapeutic management of spinal metastases. J Pain
Symptom Manage 1996;11:47-56.
37. Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol
2002;249:1357-1369.
38. Wen PY, Loeffler JS. Management of brain metastases. Oncology 1999; 13:558-
566
39. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases.
Arch Neurol 1988;45:741-744.
40. Plasswilm L, Herrlinger U, Korfel A, Weller M, KukerW, Kanz L, Thiel E, Bamberg
M. Primary central nervous system (CNS) lymphoma in immunocompetent patients.
Ann Hematol 2002;81: 415-423.
41. Lowenstein DH, Alldredge BK. Status epilepticus. New Engl J Med
1998;338:970-976.
42. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman
SA, Cairncross JG. Practice parameter: Anticonvulsant prophylaxis in patients with
newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of
the American Academy of Neurology. Neurology 2000;54:1886-1893.
43. Mamon HJ, Wen PY, Burns AC, Loeffler JS. Allergic skin reactions to
anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia
1999;40:341-344.
44. Markman M, Diagnosis and management of superior vena cava syndrome.
Cleve Clin J Med 1999;66:59-61.
45. Morales M, Llanos M, Dorta J. Superior vena cava thrombosis secondary to
Hickman catheter and complete resolution after fibrinolytic therapy. Support Care
Cancer 1997;5:67-69.
46. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for
superior vena caval obstruction in carcinoma of the bronchus (Cochrane Review).
Cochrane Database Syst Rev 2001.
47. CancerNetTM. Superior Vena Cava Syndrome (PDQ®) Supportive Care
Health Professionals (á veraldarvefnum sem: http://cancer.gov/cancerinfo/pdq/
supportivecare/superior-vena-cava/healthprofessional/).
48. de Gregorio Ariza MA, Gamboa P, Gimeno MJ, Alfonso E, Mainar A, Medrano J,
Lopez-Marin P, Tobio R, Herrera M, Percutaneous treatment of superior vena cava
syndrome using metallic stents. Eur Radiol 2003;13:853-862.
49. Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin
T, Marcus R. Prevention of central venous catheter associated thrombosis using
minidose warfarin in patients with haematological malignancies. Br J Haematol
1998;101:483-486.
50. Fiocco M, Krasna MJ. The management of malignant pleural and pericardial
effusions. Hematol Oncol Clin North Am 1997; 11:253-265.
51. DeCamp MM Jr, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive
disease of the pleura and pericardium. Chest 1997; 112:291S-295S.
52. Shepherd FA. Malignant pericardial effusion. Curr Opin Oncol 1997;9:170-
174.
53. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld
R, Pizzo PA, Rolston KVI, Shenep JL og Young LS. 2002 Guidelines for the
use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis
2002;34:730-751.
54. Quadri TL, Brown AB. Infectious complications in the critically ill patient with
cancer. Semin Oncol 2000;27:335-346.
55. Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia.
Infect Dis Clin North Am 2001;15:457-482.
56. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV. Infections in the
neutropenic patient-new views of an old problem. Hematology 2001:113-139.
57. Mermel LA, Far BM, Sherertz RJ, Raad II, O’Grady M, Harris JS, Craven DE.
Guidelines for the management of intravascular catheter-related infections. Clin
Infect Dis 2001;32:1249-1272.
58. Heussel CP, Kauczor H-U, Heussel GE, Fischer B, Begrich M, Mildenberger P,
Thelen M. Pneumonia in febrile neutropenic patients and in bone marrow and blood
stem-cell transplant recipients: Use of high-resolution computed tomography. J
Clin Oncol 1999;17:796-805.
59. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-
containing combinations for empirical antibiotic treatment of febrile neutropenic
patients: a meta-analysis. Lancet Infect Dis 2002;2:231-242.
60. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-
lactam-aminoglycoside combination therapy in cancer patients with neutropaenia.
Cochrane Database Syst Rev 2003;4.
61. Aiken SK, Wetzstein GA. Once-daily aminoglycosides in patients with
neutropenic fever. Cancer Control 2002;9:426-431.
62. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin
Infect Dis 2003;36:630-637.
63. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer
CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR.
2000 update of recommendations for the use of hematopoietic colony-stimulating
factors: evidence-based, clinical practice quidelines. J Clin Oncol 2000; 18:3558-
3585.
64. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C,
Burniat A, Steels E, Vallot F, Sculier JP. Therapeutic use of granulocyte and
granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer
patients. A systematic review of the literature with meta-analysis. Support Care
Cancer 2002;10:181-188.
65. Pagliuca A, Carrington PA, Pettengell R, Rule S, Keidan J. Guidelines on the
use of colony-stimulating factors in haematological malignancies.
Br J Haematol 2003;123:22-33.
31